Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by consultant99on Jun 20, 2017 2:26pm
376 Views
Post# 26383681

RE:June Investor Presentation

RE:June Investor PresentationLess than a week later since my last post and CTX continues to make new lows with the combined enterprise value since the spin-off now down by (26.6)%.

Pharma as a manufacturing business has but one simple objective - keep the plant running.  SInce I haven't heard of any other drug manufacturers shutting down because they had not installed new equipment to serialize bottles (have you?) is it not logical to assume that management dropped the ball on this one?

Another traunch of options were issued this year to management...
Nuvo is an amazing company to work for because compensation is not performance based.
That is why management continues to get paid regardless of the loss in market cap, shareholder value, the continuing failure of clinical trials (two WF10 and two P2%) and now the spin-off.

Promoting Jessie on the pretext of bringing a number of deals to the table was misleading to one shareholder - ME!

The BOD has failed in its duty in my humble opinion and should resign.


Bullboard Posts